Researcher Spotlight: Eduardo Edelman Saul, MD University of Texas MD Anderson Cancer Center Limited treatment options are available after frontline chemotherapy for peripheral T-cell lymphoma (PTCL), leading to poor clinical outcomes for patients who relapse. Golidocitinib, a selective Janus kinase…
Researcher Spotlight: Mallorie Heneghan, MD The University of Utah The Kellie and Jeff Fellinge Scholar Adolescents and young adults (AYAs) with lymphoma often have poor outcomes, with variable presentations observed between age groups. In particular, Dr. Heneghan is interested in…
Researcher Spotlight: Jennifer Huang, MD, PhD Fred Hutchinson Cancer Center Kanti R. Rai, MD Clinical Scholar Lisocabtagene maraleucel (liso-cel) is a chimeric antigen receptor (CAR) T-cell therapy that can be used to treat patients with relapsed or refractory chronic lymphocytic…
Researcher Spotlight: Alex Niu, MD Roswell Park Cancer Institute Eric Cohen Distinguished Scholar Chimeric antigen receptor (CAR) T-cell therapies represent a promising treatment option for many patients with relapsed lymphoma, but some patients still do not respond to therapy. By…
Researcher Spotlight: Evelyn Orlando, MD Weill Cornell Medicine Kaine Family Scholar Immunosuppressant medications used to prevent rejection after organ transplant can increase the likelihood of infection with Epstein-Barr virus (EBV). EBV infection in immunosuppressed individuals can lead to a variety…
Researcher Spotlight: Andy Bi, MD, PhD University of nebraska Medical Center Mantle cell lymphoma (MCL) is an aggressive and often treatment-refractory type of non-Hodgkin lymphoma. Using advanced sequencing techniques, Dr. Bi’s research aims to identify distinct genetic variants that contribute…
Researcher Spotlight: Dustin McCurry, MD University of texas mD anderson Cancer Center Morton Coleman, MD Innovation Fund Scholar Dr. McCurry is an instructor in the Department of Hematopoietic Biology and Malignancy at the University of Texas MD Anderson Cancer Center.…
Researcher Spotlight: Alexandra Rojek, MD the university of chicago Kristie Blum, MD Scholar Chimeric antigen receptor (CAR) T-cell therapy has improved outcomes for patients with B-cell lymphomas, but many patients still experience relapse after treatment. Dr. Rojek’s research has revealed…
Researcher Spotlight: Herman van Besien, MD weill cornell medicine Specialized immune cells from healthy donors who have previously been infected with Epstein-Barr virus (EBV) can be used to treat and kill cancer cells in patients with EBV-related lymphomas. Some subtypes…
Researcher Spotlight: Mengyang Di, MD, PhD University of Washington Runge Lymphoma Project Scholar Mosunetuzumab is a novel bispecific T cell engager used in the treatment of relapsed or refractory follicular lymphoma (FL). “Unfortunately, lymphoma still returns in most patients after…
